{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Posma JJ"],"funding":["NHLBI NIH HHS"],"pagination":["13-24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6310042"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(1)"],"pubmed_abstract":["Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation that are required for hemostasis. However, aberrant activation of coagulation can lead to thrombosis. Thrombi can cause tissue ischemia, and fibrin degradation products and activated platelets can enhance inflammation. In addition, coagulation proteases activate cells by cleavage of PARs (protease-activated receptors), including PAR1 and PAR2. Direct oral anticoagulants have recently been developed to specifically inhibit the coagulation proteases FXa (factor Xa) and thrombin. Administration of these inhibitors to wild-type mice can be used to determine the roles of FXa and thrombin in different inflammatory diseases. These results can be compared with the phenotypes of mice with deficiencies of "],"journal":["Arteriosclerosis, thrombosis, and vascular biology"],"pubmed_title":["Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases."],"pmcid":["PMC6310042"],"funding_grant_id":["R01 HL048872","R01 HL119523","R01 HL142799"],"pubmed_authors":["Posma JJ","Hisada Y","Owens AP","Antoniak S","Mackman N","Grover SP","Spronk HM"],"additional_accession":[]},"is_claimable":false,"name":"Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.","description":"Activation of the blood coagulation cascade leads to fibrin deposition and platelet activation that are required for hemostasis. However, aberrant activation of coagulation can lead to thrombosis. Thrombi can cause tissue ischemia, and fibrin degradation products and activated platelets can enhance inflammation. In addition, coagulation proteases activate cells by cleavage of PARs (protease-activated receptors), including PAR1 and PAR2. Direct oral anticoagulants have recently been developed to specifically inhibit the coagulation proteases FXa (factor Xa) and thrombin. Administration of these inhibitors to wild-type mice can be used to determine the roles of FXa and thrombin in different inflammatory diseases. These results can be compared with the phenotypes of mice with deficiencies of ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-05-29T22:26:55.22Z","creation":"2025-05-29T22:26:55.22Z"},"accession":"S-EPMC6310042","cross_references":{"pubmed":["30580574"],"doi":["10.1161/ATVBAHA.118.311655","10.1161/atvbaha.118.311655"]}}